|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.050 USD | +5.23% |
|
+54.44% | +25.52% |
| 06-09 | Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases | MT |
| 05-26 | Cartesian Therapeutics, Inc. Announces Executive Changes | CI |
| Market Cap | 253M 218M 200M 188M 353M 23.9B 357M 2.36B 922M 11.7B 948M 928M 40.54B | P/E Ratio 2026 * |
-2.18x | P/E Ratio 2027 * | -2.37x |
|---|---|---|---|---|---|
| Enterprise Value | 109M 94.02M 86.56M 81.31M 153M 10.33B 154M 1.02B 398M 5.06B 410M 401M 17.51B | EV / Sales 2026 * |
198x | EV / Sales 2027 * | -123x |
| Free-Float |
46.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cartesian Therapeutics, Inc.
| 1 day | +5.23% | ||
| 1 week | +54.44% | ||
| Current month | +20.03% | ||
| 1 month | +22.63% | ||
| 3 months | +22.46% | ||
| 6 months | +0.89% | ||
| Current year | +25.52% |
| 1 week | 6.67 |  | 9.75 |
| 1 month | 5.77 | | 9.75 |
| Current year | 5.6 | | 9.75 |
| 1 year | 5.6 | | 15.57 |
| 3 years | 5.6 | | 42.6 |
| 5 years | 5.6 | | 42.6 |
| 10 years | 5.6 | | 42.6 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 04-01 | Fiscal year | 758,001 | 2.8594% | |||
| 04-01 | Fiscal year | 22,740 | - | |||
| 04-01 | Fiscal year | 22,740 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.23% | +54.44% | -13.15% | - | 253M | |
| -0.71% | -0.97% | +50.38% | +109.48% | 54.92B | |
| -1.22% | +2.25% | +43.78% | +38.45% | 44.31B | |
| -1.43% | +4.68% | -16.02% | -20.80% | 22.96B | |
| -1.99% | +1.43% | -3.25% | +377.36% | 21.12B | |
| -2.91% | -1.18% | +7.21% | -36.53% | 16.31B | |
| -2.38% | -3.41% | +5.06% | -40.72% | 15.19B | |
| -1.70% | +0.70% | +25.27% | +172.77% | 13.32B | |
| +1.48% | +11.36% | +22.59% | - | 12.48B | |
| +4.10% | +7.02% | +104.41% | +226.33% | 11.21B | |
| Average | -0.15% | +7.08% | +22.63% | +103.29% | 21.21B | |
| Weighted average by Cap. | -0.98% | +2.06% | +29.47% | +94.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 552K 476K 438K 411K 772K 52.25M 781K 5.16M 2.01M 25.57M 2.07M 2.03M 88.59M | 402K 346K 318K 299K 562K 37.98M 568K 3.75M 1.46M 18.59M 1.51M 1.47M 64.41M |
| Net income | -122M -105M -97M -91.12M -171M -11.58B -173M -1.14B -446M -5.67B -459M -449M -19.63B | -131M -113M -104M -97.36M -183M -12.37B -185M -1.22B -477M -6.05B -491M -480M -20.97B |
| Net Debt | -144M -124M -114M -107M -201M -13.58B -203M -1.34B -523M -6.64B -538M -527M -23.02B | -302M -260M -240M -225M -423M -28.58B -427M -2.82B -1.1B -13.99B -1.13B -1.11B -48.46B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-16 | 9.050 $ | +5.23% | 368,053 |
| 26-06-15 | 8.600 $ | -9.57% | 260,129 |
| 26-06-12 | 9.510 $ | +17.99% | 877,999 |
| 26-06-11 | 8.060 $ | +8.48% | 508,010 |
| 26-06-10 | 7.430 $ | +8.47% | 545,692 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RNAC Stock
Select your edition
All financial news and data tailored to specific country editions
